Newsletter
Casirivimab and Imdevimab for Early Asymptomatic SARS-CoV-2 Infection, Hypothermia vs Normothermia for Cardiogenic Shock and Extracorporeal Membrane Oxygenation, Familial Idiopathic Dilated Cardiomyopathy, and more

JAMA Editor’s Summary

Casirivimab and Imdevimab for Early Asymptomatic SARS-CoV-2 Infection, Hypothermia vs Normothermia for Cardiogenic Shock and Extracorporeal Membrane Oxygenation, Familial Idiopathic Dilated Cardiomyopathy, and more

Editor’s Summary by Linda Brubaker, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the , issue.
February 1, 2022

Casirivimab and Imdevimab for Early Asymptomatic SARS-CoV-2 Infection, Hypothermia vs Normothermia for Cardiogenic Shock and Extracorporeal Membrane Oxygenation, Familial Idiopathic Dilated Cardiomyopathy, and more

Editor’s Summary by Linda Brubaker, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the February 1, 2022, issue.

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
Reading, Writing and Anxiety When pediatric mental health collides with the US healthcare system.